Category Archives: Myocardial Infarction

Global Post-Myocardial Infarction Market: Overview The most common term used to refer to myocardial infarction is heart-attack. In this report, TMR Research (TMR) delves into studying the factors causing the demand for post-myocardial infarction treatment. For the purpose of the study, TMR thus segments the global post-myocardial infarction market based on various parameters and then identifies opportunities prevalent across each of these segments Continue reading →

A new study provides insight into the cardiovascular health and health care services accessed by First Nations people with diabetes over a 20-year period in Ontario. Continue reading →

Market share of global Myocardial Infarction Treatment industry is dominate by companies like Bayer, Novartis, Daiichi Sankyo, Boehringer Ingelheim, Astrazeneca, Janssen Biotech, Merck, Sanofi, Pfizer and others which are profiled in this report as well in terms of Sales, Price, Revenue, Gross Margin and Market Share (2017-2018). Continue reading →

NEW ORLEANS Asthma appeared to be associated with lower mortality in patients admitted to the hospital with myocardial infarction (MI), according to the results of a large propensity-matched cohort study presented at the CHEST 2019 Annual Meeting held October 19 to 23, in New Orleans, Louisiana. Researchers hypothesized that the immunopathology profile associated with asthma might confer protection after MI. All hospital admissions with a primary diagnosis of MI (both ST-elevation MI and non-ST-elevation MI) were examined using the 2016 National Inpatient Sample Continue reading →

HOUSTON--(BUSINESS WIRE)--InGeneron, Inc., a regenerative medicine and cell therapy company, today announced the publication of promising results in developing a novel treatment for chronic ischemic heart failure using its regenerative cell therapy platform. A newly-released research paper published in the World Journal of Stem Cells provides missing pieces of evidence for a fundamental change in the treatment of chronic ischemic heart failure, showing efficacy and safety of a novel stem cell treatment in cardiology. Patients with heart failure as a consequence of previous myocardial infarction are a large and currently underserved patient population, due to the lack of regenerative treatment options Continue reading →

New York, Oct. 30, 2019 (GLOBE NEWSWIRE) -- Reportlinker.com announces the release of the report "Cardiac Biomarkers Testing Market by Type, Application and Location of Testing: Global Opportunity Analysis and Industry Forecast, 20192026" - https://www.reportlinker.com/p05793200/?utm_source=GNW The global cardiac biomarker market generated $7,638 million in 2018, and is projected to reach $18,232 million by 2026, growing at a CAGR of 11.4%. Cardiac biomarkers are protein-based traceable substances used as an indicator of biologic state as well as for diagnostic and prognostic purposes associated with heart. Continue reading →

Raymond Kwong, director of cardiac magnetic resonance imaging at Brigham and Womens Hospital, associate professor of medicine at Harvard Medical School, and lead investigator of the Stress CMR Perfusion Imaging in the United States (SPINS) study, discusses the high diagnostic and prognostic power of Heart MRIs, as well as their ability to reduce downstream costs for patients. Multiple studies show that heart magnetic resonance imaging (MRI), a modality for non-invasive, non-radiation assessment of the function and structure of the heart and cardiovascular system, is highly accurate in the detection of obstructive coronary stenosis. Continue reading →

A detailed segmentation-wise analysis included in the study highlights key segments of the ICU Equipment Carrier Market, and offers associated market numbers that allude at their growth potential at present as well as in the assessment period. Continue reading →

Ischemic heart disease (IHD), refers to a group of diseases which includes stable angina, unstable angina, myocardial infarction, and sudden cardiac death. It is within the group of cardiovascular diseases of which it is the most common type. A common symptom is chest pain or discomfort which may travel into the shoulder, arm, back, neck, or jaw Continue reading →

Tiechao Jiang,1,2 Lirong Zhang,3 Mei Ding,1,2 Min Li4 1Department of Cardiovascular Medicine, China-Japan Union Hospital of Jilin University, Changchun 130033, Peoples Republic of China; 2Jilin Provincial Precision Medicine Key Laboratory for Cardiovascular Genetic Diagnosis, Changchun 130033, Peoples Republic of China; 3Department of Pathology, China-Japan Union Hospital of Jilin University, Changchun 130033, Peoples Republic of China; 4Department of Clinical Laboratory, China-Japan Union Hospital of Jilin University, Changchun 130033, Peoples Republic of China Correspondence: Mei DingDepartment of Cardiovascular Medicine, China-Japan Union Hospital of Jilin University, 126 Xiantai St, Erdao, Changchun 130033, Peoples Republic of ChinaTel +86-431-8499 5258Email LeahRamosjsr@yahoo.comMin LiDepartment of Clinical Laboratory, China-Japan Union Hospital of Jilin University, 126 Xiantai St, Erdao, Changchun 130033, Peoples Republic of ChinaTel +86-431-8499 5646Email m6855512helin8@163.com Background: Myocardial infarction is the leading cause of damage to the heart and is classified as a major cause of death related to cardiovascular disease. In the present study, we intended to investigate the protective effect of vasicine (VAS) against myocardial infarction in rats, and its mechanism.Methods: Myocardial infarction was induced by isoproterenol (ISO, 100 mg/kg) at an interval of 24 h for 2 days. Different doses of VAS (2.5, 5, and 10 mg/kg body weight) were administered to the rats. Continue reading →